Learn, Analyse & Invest
only with
only with
+91
Download Orca
Piramal Pharma Ltd.
Piramal Pharma
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹215.21 Cr.
Subsidiaries
No Subsidiaries Data available
Management
1. Tanya Sanish
Company Secretary & Compliance Officer
2. Nandini Piramal
Chairperson
3. Peter DeYoung
Executive Director
4. Vivek Valsaraj
Whole Time Director & Chief Financial Officer
5. S Ramadorai
Non Executive Independent Director
6. Peter Stevenson
Non Executive Independent Director
7. Jairaj Purandare
Non Executive Independent Director
8. Vibha Paul Rishi
Non Executive Independent Director
9. Sridhar Gorthi
Non Executive Independent Director
10. Amit Jain
Nominee Director of CA Alchemy Investments
11. Nathalie Leitch
Non Independent & Non Executive Director
Contact Information
Company Address
Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, L B S Marg Kurla (West)
Mumbai, Maharashtra - 400070
www.piramalpharma.com
shareholders.ppl@piramal.com
Registrar
MUFG Intime India Pvt Ltd.
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra
Phone: +91 810 811 8484
Email: rnt.helpdesk@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/
Company Profile
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across several global facilities and a global distribution network in hundreds of countries. It includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.
PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.
Business area of the company
The company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across many global facilities and a global distribution network in hundreds of countries. It includes PPS, PCC and the India Consumer Healthcare business, selling over-the-counter products.
